Diabetes Recalls: Separate HbA1c Testing, Foot Review and Clinical Follow-Up
Build diabetes recall tasks from the current individual plan, preserving test dates, foot-risk review and result assessment without a universal 90-day timer.
Use a preventive health review to decide which evidence-based actions are appropriate for an individual, considering age, relevant risk, prior results, current symptoms and informed choice. Screening of an apparently well person, investigation of symptoms and monitoring of known disease are different pathways. An annual invitation should not automatically produce the same blood-test or cancer-screening package for every family member.
Indian primary-care clinics designing preventive reviews and recall services for adults and families, with responsibility for explaining results and arranging follow-through.
A screening offer asks whether an apparently well person belongs to a group for whom a particular test or assessment has a useful evidence-based purpose. A patient with symptoms may instead need diagnostic assessment. A person already receiving care for a condition may need monitoring of that condition.
WHO Europe's screening guide describes potential benefits alongside harms, cost and the need for a complete quality-assured pathway. It is not a list of tests every healthy person should buy. More tests do not automatically mean a better preventive service.
Start the review with the patient's concerns and existing care. A new symptom should not be diverted into a routine 'wellness panel' merely because the appointment was booked under preventive care.
Identify the question each proposed action is meant to answer and what would happen after each possible result. If the clinic cannot explain the next step or arrange it, a test package can create unresolved information rather than useful prevention.
Keep preventive discussion broader than laboratory orders. Relevant counselling, vaccination review or risk-factor assessment may be part of the clinician's plan, without every discussion generating another test.
Source: WHO Europe: Screening programmes, a short guide, 6 February 2020
India's NP-NCD Operational Guidelines 2023–2030 describe population-based screening for people aged 30 years and above for hypertension, diabetes and cancers of the oral cavity, cervix and breast, within the programme's appropriate pathways. This is important local context, not authority for one identical annual package for everyone over 30.
The relevant individual criteria still matter: the condition being considered, applicable anatomy and history, previous assessment, risk and the method recommended by the responsible clinician. A broad age label should not substitute for these decisions.
The programme connects screening with referral, treatment and follow-up. A private clinic drawing on that context should likewise plan what happens after a finding, rather than treat specimen collection or a camp attendance count as the endpoint.
Record which guidance and version supports an offer and which parts of the patient's history remain uncertain. If outside screening was performed, obtain useful details before repeating it solely because the clinic's own chart is empty.
An invitation can be annual for administrative convenience while individual actions have different clinically appropriate intervals. Keep the review date, each test's due basis and any diagnostic referral separate.
Source: MoHFW: NP-NCD Operational Guidelines 2023–2030, hosted by NHM Mizoram
Use a short decision record during the clinical review. It should capture the question, relevant eligibility, existing evidence, benefits and limitations discussed, the person's decision and the next owner.
Do not treat a normal previous result as permanent clearance, or an absent record as proof that a test was never done. Preserve the date and source, then let the clinician decide whether the information is sufficient.
Explain possible consequences in plain language. A positive screening result may need further assessment; a negative result does not rule out every disease or cancel new symptoms. Avoid language such as 'complete cancer clearance'.
Where several tests are offered, explain them individually enough for a meaningful choice. A preselected package consent box can hide a test the patient does not understand or want.
The table is an original review framework, not a screening eligibility algorithm.
On a narrow screen, scroll the table horizontally to read all columns.
| Decision | What to record | Reason it matters |
|---|---|---|
| Purpose | Screening, symptom investigation, known-disease monitoring or another defined action | Prevents a single annual-panel label from hiding different care pathways |
| Eligibility | Relevant individual criteria and guidance used | Age alone may not settle the choice |
| Previous evidence | Actual date, method, result/source and follow-up already arranged | Avoids unnecessary duplication and false reassurance |
| Benefits and limits | Plain-language discussion of useful outcomes and possible harms | Supports informed choice rather than fear-based uptake |
| Patient decision | Agreed, declined, deferred or needing further discussion | A declined offer is not a positive test or failed treatment |
| Result pathway | Reviewer, communication and referral/confirmation arrangement | A test result needs an accountable next step |
Consider an original fictional group of 40 people invited to an individual preventive review. Twenty-eight agree, eight decline and four have an unknown contact outcome. Those categories total 40; unknown contact is not refusal.
After the 28 reviews, 20 people each have one agreed screening action due, five have no additional screening action due under their reviewed plans, and three need diagnostic assessment of symptoms. These are 28 distinct review outcomes.
Suppose 15 of the 20 agreed screening actions are completed with their defined result-review evidence, leaving five open. Completion is 75% of agreed due actions. It is 37.5% of all 40 invitations, a different measure with a different denominator.
The five people with no action due should not be sent unnecessary tests to improve uptake. The three symptomatic people need the appropriate diagnostic pathway and should not be counted as screening positives merely because they were referred.
The eight people declining review may still use the clinic for other care. Record their choice and contact preferences without portraying it as loss of patient loyalty. A preventive service should support informed decisions, not maximise tests per invitation.
A family may want a convenient shared appointment day, but each person needs an individual record, discussion and decision. One payer or household organiser does not automatically have permission to see everyone's results.
Offer appropriate privacy and language assistance. Sensitive history may not be disclosed in front of a spouse, parent or employer. Do not make a public reception questionnaire the only route to an individual assessment.
Agree how results will be reviewed and communicated, including outside laboratory reports. A PDF sent to the patient does not establish clinical interpretation or understanding of the next step.
If further assessment is needed, identify the receiving service and a person responsible for tracking the handover. A referral issued but never arranged remains a different outcome from a completed diagnostic decision.
Review unresolved results before inviting another batch. The capacity to explain and act on findings is part of the service; increasing invitations without that capacity can increase unfinished care.
The fictional cohort has 28 agreed reviews, eight declines and four unknown contacts. The reviews identify 20 agreed screening actions, five people with no additional action due and three diagnostic assessments. Fifteen of twenty screening actions are completed: 75% of that defined group, not proof that everyone invited benefited.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. The review should determine appropriate individual actions from evidence, history and current circumstances. An invitation frequency does not establish the need or interval for every test.
Not generally. Symptoms may require diagnostic assessment, while screening usually concerns an apparently well population meeting relevant criteria. Preserve the actual clinical purpose.
No. Its population-screening context includes defined conditions and pathways. The individual action still needs appropriate eligibility, method, clinical judgement and follow-through.
No. Every test has scope and limitations. A normal result does not exclude every condition or remove the need to assess new symptoms.
Do not assume that. Establish each person's permitted recipient and disclosure arrangement, separate from payment or booking coordination.
Updated on . Original preventive-service planning with Indian programme context and WHO screening principles. It does not prescribe a universal test panel, screening interval or eligibility decision for an individual. No independent clinical or legal review is claimed.
Indian population-screening programme context; not a prescription for the same annual test panel for every family member.
Explains screening benefits, harms and the need for a complete pathway; the clinic selection examples are original.
Build diabetes recall tasks from the current individual plan, preserving test dates, foot-risk review and result assessment without a universal 90-day timer.
Coordinate family appointments and support while keeping individual records, recipient permissions, payer roles and contact changes distinct.
Track referral decisions, appointments, specialist reports and clinical follow-through using a reconciled register, with ownership of unresolved cases.
Build the fictional 40-person review cohort with agreed screening, no-action-due, diagnostic and declined outcomes. Show individual permission, result ownership and distinct denominators.
Request a clinic demo